NCT07510815 (DUAL-MESO-NK) is a Phase 1, PHASE2 clinical trial of EB-MF-CAR-NK-01 in Malignant Pleural Mesotheliomas, sponsored by Beijing Biotech.

Who is sponsoring NCT07510815?

NCT07510815 is sponsored by Beijing Biotech.

What drugs are being tested in NCT07510815?

Interventions in NCT07510815: EB-MF-CAR-NK-01, Fludarabine, Cyclophosphamide.

What condition does NCT07510815 study?

NCT07510815 studies Malignant Pleural Mesotheliomas.

Is NCT07510815 still recruiting?

NCT07510815 is currently recruiting now. Last updated 6 April 2026.

Last reviewed 2026-04-06 · How we verify

NCT07510815: DUAL-MESO-NK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma

Recruiting now Phase 1, PHASE2 Last updated 6 April 2026

What this trial tests

Phase 1, PHASE2 trial testing EB-MF-CAR-NK-01 in Malignant Pleural Mesotheliomas in 36 participants. Currently enrolling.

Timeline

2 March 2026

Primary endpoint
14 March 2027

17 April 2028

Quick facts

Lead sponsor	Beijing Biotech
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	2 March 2026
Primary completion	14 March 2027
Estimated completion	17 April 2028
Sites	1 location across China

Drugs / interventions tested

EB-MF-CAR-NK-01
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Malignant Pleural Mesotheliomas — all drugs for Malignant Pleural Mesotheliomas →

Sponsor

Beijing Biotech — full company profile →

Who can join

Adults 18 to 75, any sex, with Malignant Pleural Mesotheliomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This example study evaluates locoregional allogeneic dual-target mesothelin/FAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma. Eligible participants must have central confirmation of MSLN-positive tumor cells and FAP-positive tumorassociated stroma. The phase 1 portion defines the recommended phase 2 dose and schedule, and the phase 2 expansion explores preliminary antitumor activity, persistence, and biomarker response in pleural and peritoneal disease cohorts.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Beijing Biotech trials

Trials by the same sponsor.

NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
NCT07523542 — SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus · Phase 1, PHASE2 · recruiting
NCT07510828 — PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07523529 — Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07500220 — Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07510815 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Biotech
Last refreshed: 6 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07510815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing